Добірка наукової літератури з теми "Anti-TB Therapy"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Anti-TB Therapy".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Anti-TB Therapy"
Ye, L., L. Wu, J. Tang, R. Mao, and Q. Cao. "P502 Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from China." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i464. http://dx.doi.org/10.1093/ecco-jcc/jjab232.629.
Повний текст джерелаMandic, Dragana, Radmila Curcic, Gordana Radosavljevic, Nemanja Damjanov, Dusan Stefanovic, Igor Mitic, and Aleksandar Dimic. "Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors." Srpski arhiv za celokupno lekarstvo 137, no. 3-4 (2009): 211–16. http://dx.doi.org/10.2298/sarh0904211m.
Повний текст джерелаMazlun, Muhamad Harith, Siti Fatimah Sabran, Maryati Mohamed, Mohd Fadzelly Abu Bakar, and Zunoliza Abdullah. "Phenolic Compounds as Promising Drug Candidates in Tuberculosis Therapy." Molecules 24, no. 13 (July 4, 2019): 2449. http://dx.doi.org/10.3390/molecules24132449.
Повний текст джерелаIbrahim, Chandra Satria. "Anti-TB Drug for Tuberculosis Spondylitis." Neurologico Spinale Medico Chirurgico 1, no. 2 (August 7, 2018): 18. http://dx.doi.org/10.15562/nsmc.v1i2.96.
Повний текст джерелаNoguera-Julian, Antoni, Joan Calzada-Hernández, Folke Brinkmann, Robindra Basu Roy, Olga Bilogortseva, Michael Buettcher, Isabel Carvalho та ін. "Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study". Clinical Infectious Diseases 71, № 10 (4 грудня 2019): 2561–69. http://dx.doi.org/10.1093/cid/ciz1138.
Повний текст джерелаKumar, P., S. K. Vuyyuru, B. Kante, P. Sahu, S. Goyal, D. Madhu, S. Jain, et al. "P531 Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i484. http://dx.doi.org/10.1093/ecco-jcc/jjab232.658.
Повний текст джерелаPaz, M. E. Pinto, L. Bueno Lazo, D. Carrera Palao, D. F. Pinto Ruiz, M. R. Huaman, and A. M. Quispe. "Efficacy and safety of oncoplastic surgery plus drug therapy for chronic tuberculous granulomatous mastitis." International Journal of Tuberculosis and Lung Disease 24, no. 6 (June 1, 2020): 585–90. http://dx.doi.org/10.5588/ijtld.19.0478.
Повний текст джерелаSugiyama, Yuya, Nobuhiro Ueno, Shion Tachibana, Yu Kobayashi, Yuki Murakami, Takahiro Sasaki, Aki Sakatani, et al. "The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report." Medicine 102, no. 28 (July 14, 2023): e34331. http://dx.doi.org/10.1097/md.0000000000034331.
Повний текст джерелаHidayat, Edi Yanuarto, Nasirun Zulqarnain, and Muchlis Achsan Udji Sofro. "Perbandingan Gambaran Foto Toraks Pasien TB-HIV Dua dan Enam Bulan Pengobatan Anti-Tuberkulosis + Anti-Retroviral." Jurnal Radiologi Indonesia 1, no. 2 (September 1, 2015): 91–98. http://dx.doi.org/10.33748/jradidn.v1i2.12.
Повний текст джерелаFrolova, K. S., and S. E. Borisov. "RISK OF DEVELOPING ACTIVE TB IN IBD PATIENTS TREATED WITH ATNI-TNF." Koloproktologia, no. 1 (March 30, 2018): 49–56. http://dx.doi.org/10.33878/2073-7556-2018-0-1-49-56.
Повний текст джерелаДисертації з теми "Anti-TB Therapy"
Ngandu, Jean Pierre Kabue. "Coreceptor expression and T lymphocyte subset distribution in HIV-infected and TB co-infected South African patients on anti-retroviral therapy." Thesis, Stellenbosch : University of Stellenbosch, 2009. http://hdl.handle.net/10019.1/2219.
Повний текст джерелаENGLISH ABSTRACT: In 2007, AIDS caused an estimated 2.1 millions deaths worldwide; about 70% in sub-Saharan Africa. HIV preferentially targets activated CD4 T cells, expressing the major HIV receptor CD4, as well as the major chemokine coreceptors CCR5 and CXCR4. These coreceptors play a prominent role during HIV cell entrance phase, HIV transmission and also disease progression. They have been found to be differentially expressed by CD4 T cell subsets. Tuberculosis coinfection may enhance immune activation in vivo thus accelerating HIV disease progression and has become a major challenge in the control of TB in Africa. Introduction of HAART has reduced disease progression to AIDS, as well as risk of further morbidity and mortality. HAART results in a rapid decline of viral load and an initial increase of peripheral CD4 count, however little is known on the effect of HAART in regulation of coreceptor expression, immune activation status and CD4 T cell subset distribution in HIV infection and HIV/TB coinfection. This study is a cross-sectional analysis of coreceptor expression, immune activation status and CD4 T cell subpopulation distribution in South African HIV and HIV/TB coinfected patients before and after ARV. A total of 137 South African individuals were investigated, comprising 15 healthy normal donors (healthy subgroup), 10 patients with active pulmonary tuberculosis (PTB subgroup), 33 HIV-1 positive patients without active PTB (HIV subgroup), 23 positive patients with active PTB (HIV/PTB subgroup), 36 HIV-1 positive patients on ARV (HIV on ARV subgroup) and 20 HIV-1 positive patients with active PTB on ARV (HIV/PTB on ARV subgroup). CD4 absolute count and plasma viral load were determined for all donors. Freshly isolated PBMC were classified by flow cytometry into the following CD4+ T lymphocyte subsets: naïve (CD45+, CD27+), effector memory (CD45-, CD27-), central memory (CD45-, CD27+), and effector (CD45+, CD27-). Coreceptor expression and activation status was assessed by CCR5, CXCR4 and CD38 expression on CD4 T cell subsets. HIV, TB and HIV/TB coinfection was associated with a decrease in percentage CCR5+ T cells as compared to healthy controls, with the HIV/TB group showing the most extensive decrease. In treatment naive patients, CD4 T cells showed elevated surface expression of CCR5 and CD38 as determined by mean fluorescence intensity in HIV/TB co-infection compared to HIV infection alone. The percentage of antigen-experienced cells was higher in the HIV/TB co-infected group compared to the HIV group. The percentage of naïve T cells was decreased in both the HIV infected and the HIV/TB co-infected groups compared to healthy controls. HIV patients with more than 6 months of ARV showed decreased CCR5 and CD38 surface level expression in the HIV and the HIV/ TB co-infected subgroups. An increased percentage of naïve T cells was observed in the HIV infected subgroup, but not in the HIV/TB subgroup, similarly, a decreased percentage of antigen-experienced cells was observed in the HIV subgroup, but not in the HIV/TB co-infected subgroup. A positive correlation was found between CCR5 and CD38 expression, and CXCR4 and CD38 expression (Spearman coefficient of correlation respectively: r=0.59, p<0.001 and r=0.55, p<0.001). Furthermore we found plasma viral load positively associated with CD38 expression (r=0.31, p<0.001) and percentage activated CCR5+ expressing CD4 T cells positively related to viral load (r=0.31, p<0.001). Percentage naïve CD4 T cells was positively associated with CD4 count (r=0.60, p<0.001) and negatively correlated to viral load (r=-0.42, p<0.001). These results indicate that TB coinfection exacerbates certain aspects of dysregulation of CD4 T cell homeostasis and activation caused by HIV infection. In addition, ARV-associated decrease in coreceptor expression, immune activation status and a normalisation of CD4 T cell subset distribution was observed in HIV infected individuals, but not in HIV/TB coinfection. Despite viral suppression after ARV treatment, the decline in the immune activation marker CD38 and coreceptor CCR5 expression, increase in percentage naïve CD4 T cells and decrease of antigen-experienced cells did not reach the levels displayed in the healthy control group. This may indicate that ongoing (albeit reduced) T cell immune activation may occur in the presence of ARV. Further longitudinal studies are needed to closely monitor immune activation during ARV treatment. This study highlighted an association of TB disease with immune activation in HIV infection, the importance of T-cell activation in HIV pathogenesis and its impact on ARV treatment. Further studies are needed to identify causative factors that may lead to a persistent immune activation status during ARV treatment, and how TB coinfection confounds normal responses to ARV.
AFRIKAANSE OPSOMMING: In 2007 was ongeveer 2.1 miljoen sterftes wêreldwyd veroorsaak deur VIGS; ongeveer 70% in Sub-Sahara Afrika. CD4 T selle is die hoof teiken van MIV, aangesien dit die primêre CD4 reseptor, sowel as een of beide van die vernaamste chemokien koreseptore CCR5 en CXCR4 vrystel. Hierdie koreseptore speel ‘n prominente rol wanneer die MIV die sel binnedring, asook tydens MIV oordrag en verloop van die siekte. Dit word ook deur verskillende fraksies van CD4 T selle vrygestel. Gelyktydige TB infeksie mag immuunaktivering in vivo verhoog en dus die siekeproses versnel. MIV het ‘n groot uitdaging geword in die beheer van TB in Afrika. Bekendstelling van HAART het die ontwikkeling van VIGS vertraag, asook die risiko van verdere morbiditeit en mortaliteit. HAART veroorsaak ‘n vinnige afname in virale lading ‘n toename in CD4 telling, hoewel die spesifieke invloed van HAART op die regulering van koreseptor vrystelling, immuunaktivering en verspreiding van CD4 fraksies in MIV en MIV/TB infeksies nog onduidelik is. Hierdie studie het gepoog om koreseptor vrystelling, immuunaktiveringstatus en die verspreiding van CD4 subpopulasies in pasiënte met MIV en MIV/TB voor en na ARV behandeling te ondersoek. ‘n Totaal van 137 Suid-Afrikaanse individue is ondersoek en die studiegroep het bestaan uit 15 normale persone (gesonde subgroep), 10 pasiënte met aktiewe pulmonale TB (PTB subgroup), 33 MIV positiewe pasiënte sonder PTB (MIV subgroep), 23 MIV positiewe pasiënte met aktiewe PTB (MIV/PTB subgroep), 36 MIV positiewe pasiënte op ARV (MIV op ARV subgroep) en 20 MIV positiewe pasiënte met aktiewe PTB op ARV (MIV/PTB op ARV subgroep). Absolute CD4 telling en virale ladings was bepaal vir alle deelnemers. Vars geïsoleerde perifere bloed mononukleêre selle is geklassifiseer deur middel van vloeisitometrie as die volgende CD4 T limfosiet subgroepe: naïewe selle (CD45+, CD27+), effektor geheueselle (CD45-, CD27-), sentrale geheueselle (CD45-, CD27+), en effektor selle (CD45+, CD27-). Koreseptor vrystelling en aktivering was beoordeel volgens CCR5, CXCR4 en CD38 vrystelling op CD4 T sel subgroepe. HIV, TB en MIV/TB ko-infeksie is geassosieer met ‘n afname in die persentasie CCR5+ T selle, vergeleke met gesonde kontroles, waar die MIV/TB subgroep die grootste afname getoon het. In onbehandelde pasiënte het die CD4 T selle verhoogde vrystelling van CCR5 en CD38 op die oppervlakte getoon en dit is bevestig deur die gemiddelde fluoresserende vii intensiteit in die MIV/TB subgroep vergeleke met die subgroep met slegs MIV. Die MIV/TB subgroep het verder ook ‘n verhoogde persentasie totale geheue T selle getoon vergeleke met die MIV subgroep. Die persentasie naïewe T selle was egter verlaag in beide die MIV en MIV/TB subgroepe vergeleke met normale kontroles. MIV pasiënte wat langer as 6 maande op ARV behandeling was in beide die MIV en MIV/TB subgroepe, het ‘n verlaagde vrystelling van CCR5 en CD38 op die oppervlakte van die CD4 selle getoon. ‘n Verhoogde persentasie naïewe T selle het in die MIV subgroep voorgekom, maar nie in die MIV/TB subgroup nie. ‘n Soortgelyke tendens is gevind waar die persentasie totale geheueselle verlaag was in die MIV subgroep, maar nie in die MIV/TB subgroep nie. ‘n Positiewe korrelasie is gevind tussen CCR5 en CD38 vrystelling, asook CXCR4 en CD38 vrystelling (Spearman korrelasie koëffisiënt: r=0.59, p<0.001 en r=0.55, p<0.001 onderskeidelik). Verder het die plasma virale lading ‘n positiewe assosiasie getoon met CD38 vrystelling (r=0.31, p<0.001) en die persentasie geaktiveerde CCR5+ vrystellende CD4 T selle met virale lading (r=0.31, p<0.001). Die persentasie naïewe CD4 T selle het ‘n positiewe assosiasie getoon met CD4 telling (r=0.60, p<0.001) en ‘n negatiewe korrelasie met virale lading (r=-0.42, p<0.001). Volgens hierdie resultate vererger TB ko-infeksie sekere aspekte van die disregulasie van CD4 T selhomeostase en aktivering as gevolg van MIV infeksie. Verder kon ‘n ARVgeassosieerde afname in koreseptor vrystelling, immuunaktivering en normalisering van CD4 T sel fraksies bespeur word in die MIV subgroep, maar nie in die MIV/TB subgroep nie. Ten spyte van virale onderdrukking veroorsaak deur ARV behandeling, het die afname in die immuunmerker CD38 en koreseptor CCR5, toename in die persentasie naïewe CD4 selle en afname in totale geheue CD4 T selle nie die vlakke van die normale kontrolegroep bereik nie. Dit is moontlik dat volgehoue verlaagde T sel immuunaktivering nog steeds mag plaasvind in die teenwoordigheid van ARV. Verdere longitudinale studies is nodig om immuunaktivering tydens ARV behandeling te monitor. Hierdie studie het die belangrikheid van T sel aktivering in MIV patogenese en dit impak daarvan op ARV behandeling beklemtoon. Verdere studies is nodig om moontlike oorsake of bydraende faktore te identifiseer wat tot volgehoue immuunaktivering tydens ARV behandeling kan lei, asook tot mate waartoe TB ko-infeksie kan inmeng met die normale werking van ARV behandeling.
Abuhammad, Areej. "Arylamine N-Acetyltransferases from mycobacteria : investigations of a potential target for anti-tubercular therapy." Thesis, University of Oxford, 2013. http://ora.ox.ac.uk/objects/uuid:3f571661-7b51-4fa8-bf5e-2adff9269c59.
Повний текст джерелаЧастини книг з теми "Anti-TB Therapy"
Bhaskar, Ashima, Ved Prakash Dwivedi, and Vinay Kumar Nandicoori. "Eliminating Mycobacterial Persistence: Novel Targets for Anti-TB Therapy." In Pathogenicity and Drug Resistance of Human Pathogens, 57–79. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-32-9449-3_3.
Повний текст джерелаSaravanan, Muthupandian, Kebret Duche, Tsehaye Asmelash, Araya Gebreyesus, Anima Nanda, and Selvaraj Arokiyaraj. "Nanomedicine as a Newly Emerging Approach Against Multidrug-Resistant Tuberculosis (MDR-TB)." In Biomedical Engineering, 941–60. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-3158-6.ch041.
Повний текст джерелаSaravanan, Muthupandian, Kebret Duche, Tsehaye Asmelash, Araya Gebreyesus, Anima Nanda, and Selvaraj Arokiyaraj. "Nanomedicine as a Newly Emerging Approach Against Multidrug-Resistant Tuberculosis (MDR-TB)." In Integrating Biologically-Inspired Nanotechnology into Medical Practice, 50–73. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0610-2.ch003.
Повний текст джерелаRani, Sarita, Ankur Kaul, Anil Kumar Mishra, and Umesh Gupta. "Extra-Pulmonary TB." In Advances in Medical Diagnosis, Treatment, and Care, 91–116. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-0307-2.ch005.
Повний текст джерелаKhiewkhern, Santisith, Nuchnapa Pratumchai, Parichart Sattayarak, Patcharin Phuwilert, Supattra Noo-In, and Naree Areeruk. "The Information from Medical Data Based: Prevalence and Expected Median Survival Time of Drug-Induced Hepatotoxicity Among Thai Patients with TB." In Studies in Health Technology and Informatics. IOS Press, 2021. http://dx.doi.org/10.3233/shti210282.
Повний текст джерелаAhmed, Nazmin, Md Shahidul Islam Khan, and Md Kamrul Ahsan. "Pott’s Paraplegia." In Paraplegia - New Insights [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.107851.
Повний текст джерелаKalaiselvan, Vivekanandan, Shatrunajay Shukla, Santhanakrishnan Ramesh Kumar, Nikita Mishra, Pawan Kumar, and Rajeev Singh Raghuvanshi. "Adverse Drug Reactions Associated with Anti-Tuberculosis Therapy." In New Insights into the Future of Pharmacoepidemiology and Drug Safety [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.97246.
Повний текст джерелаOrmerod, L. Peter. "How to manage a patient on anti-TB therapy with abnormal liver enzymes." In Infectious Diseases, 349–50. Elsevier, 2010. http://dx.doi.org/10.1016/b978-0-323-04579-7.00208-2.
Повний текст джерелаOrmerod, L. Peter, and Thomas C. Bailey. "How to Manage a Patient on Anti-TB Therapy with Abnormal Liver Enzymes." In Infectious Diseases, 308–9. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-7020-6285-8.00204-5.
Повний текст джерелаТези доповідей конференцій з теми "Anti-TB Therapy"
Tiwari, Mani, Mahendra Patel, and Khyati Shamaliya. "Peripheral neuropathy in XDR-TB patients on second line anti-tubercular therapy." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2710.
Повний текст джерелаKuzhko, Mykhailo, Mykola Gumeniuk, Dmytro Butov, Tetiana Tlustova, Oleksii Denysov, and Tetiana Sprynsian. "Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa3496.
Повний текст джерелаSiagian, P., B. Y. M. Sinaga, E. Efriyandi, and U. Martin. "The Emerging of a Primary Extensive Drug Resistance Tuberculosis (XDR-TB) Without Previous Anti Tuberculosis Therapy." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5137.
Повний текст джерелаFildan, Ariadna Petronela, Gheorghita Voicu, Livia Floca, Elis Curtmola та Elena Dantes. "Latent tuberculosis infection prevalence and risk of developing active TB among patients eligible for starting anti-TNFα therapy". У Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2973.
Повний текст джерелаSathyapriya, Sarah, Loh Chow Chin, and Wan Hazabbah Wan Hitam. "Presumed Ocular Tuberculosis – Challenges in Diagnosis." In 2nd International Conference on Public Health and Well-being. iConferences (Pvt) Ltd, 2022. http://dx.doi.org/10.32789/publichealth.2021.1010.
Повний текст джерелаRuksenaite, Justina, Thomas Ward, George Tsaknis, and Syed-Fayyaz Hussain. "Prevention of latent TB reactivation in rheumatology patients prior to anti-TNF therapy: Evaluation of a risk stratification strategy in a low prevalence area." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2974.
Повний текст джерела